Natco Pharma Faces Sustained Stock Decline Amid Broader Market Challenges

Natco Pharma, a midcap player in the Pharmaceuticals & Drugs industry, has experienced significant volatility in its stock performance. On February 18, 2025, the stock declined by 5.14%, marking a new 52-week low of Rs. 825.4. This decline is part of a broader trend, as Natco Pharma has underperformed its sector by 3.88% today and has seen a consecutive fall over the past eight days, resulting in a substantial 37.77% decrease in returns during this period.
In terms of moving averages, Natco Pharma is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a sustained downward trend. The stock's one-day performance of -4.69% contrasts sharply with the Sensex, which only fell by 0.36%. Over the past month, Natco Pharma has faced a staggering 33.09% decline, while the Sensex has seen a modest decrease of 1.17%. These metrics highlight the challenges faced by Natco Pharma in the current market environment.